Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study [PDF]
, 2006 OBJECTIVE: In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice.
Bilušić, Marinko +6 more
core +1 more source
Dyspepsia in Nonsteroidal Anti-inflammatory Drugs Gastropathy [PDF]
, 2011 Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) gastropathy is a common complication, which has characteristic symptoms of dyspepsia syndrome. Mostly, it includes epigastric discomfort with bloating and nausea.
Daldiyono, D. (Daldiyono) +4 more
core +1 more source
Is Misoprostol Cost-effective in the Prevention of Nonsteroidal Anti-inflammatory Drug—Induced Gastropathy in Patients With Chronic Arthritis? [PDF]
, 1994 Whether misoprostol, a synthetic prostaglandin E1 analogue, should be routinely prescribed along with nonsteriodal anti-inflammatory drugs (NSAIDS) to prevent gastric damage is of great clinical importance and has profound cost implications. No consensus
Johannesson, Magnus +2 more
core +1 more source
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]
, 2020 Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P +8 more
core +2 more sources
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
Pharmaceuticals, 2010 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the isoenzymes COX-1 and COX-2 of cyclooxygenase (COX). Renal side effects (e.g., kidney function, fluid and urinary electrolyte excretion) vary with the extent of COX-2-COX-1 selectivity and the ...
Walter H. Hörl
doaj +1 more source
Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study [PDF]
, 2018 This work was partially funded by the “Accion Transversal del Cancer”, approved on the Spanish Ministry Council on the 11th October 2007; The Instituto de Salud Carlos III-FEDER [PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León ...
De Pedro, M. +4 more
core +2 more sources
A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy [PDF]
, 2017 Bone involvements in chronic lymphocytic leukemia (CLL) are considered rare events, and the English-language medical literature describes them only in sporadic case reports. Consequently, robust indications for a rational clinical management are lacking.
Al Sayyad, Said +12 more
core +1 more source
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein [PDF]
, 2008 Background: Epidemiological studies have suggested that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of Alzheimer's disease (AD).
Czirr, Eva +8 more
core +1 more source
New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]
, 2017 Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core +1 more source
PPARγ, neuroinflammation, and disease [PDF]
, 2004 Background Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear transcription factors that are activated by fatty acids and their derivatives.
Mrak Robert E, Landreth Gary E
core +2 more sources